Enteris BioPharma Revenue and Competitors
Estimated Revenue & Valuation
- Enteris BioPharma's estimated annual revenue is currently $1.2M per year.
- Enteris BioPharma's estimated revenue per employee is $77,500
Employee Data
- Enteris BioPharma has 16 Employees.
- Enteris BioPharma grew their employee count by 7% last year.
Enteris BioPharma's People
Name | Title | Email/Phone |
---|---|---|
1 | COO | Reveal Email/Phone |
2 | CMO | Reveal Email/Phone |
3 | VP, Product Development & Quality Control | Reveal Email/Phone |
4 | Director Quality Assurance | Reveal Email/Phone |
5 | Quality Assurance Manager | Reveal Email/Phone |
6 | QC Manager | Reveal Email/Phone |
7 | Manager, Business Development | Reveal Email/Phone |
8 | Sr. Analytical Development Scientist | Reveal Email/Phone |
9 | Analytical Chemist | Reveal Email/Phone |
10 | Senior Production Manufacturing Tech II | Reveal Email/Phone |
Enteris BioPharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $8.5M | 55 | -21% | N/A | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $8.5M | 55 | -29% | N/A | N/A |
#4 | $108.5M | 500 | 2% | N/A | N/A |
#5 | $0.8M | 5 | 0% | N/A | N/A |
#6 | $0.6M | 4 | 0% | N/A | N/A |
#7 | $14.7M | 68 | -23% | $206.4M | N/A |
#8 | $492.2M | 1503 | -15% | $568M | N/A |
#9 | $1.1M | 7 | -42% | N/A | N/A |
#10 | $4.5M | 29 | 0% | N/A | N/A |
What Is Enteris BioPharma?
Enteris BioPharma is a clinical stage biopharmaceutical company offering innovative formulation solutions built around its proprietary oral drug delivery technologies. In addition to its formulation development expertise, Enteris BioPharma has a 32,000 square foot GMP facility in Boonton, New Jersey, offering an expanding range of manufacturing and development services. Enteris BioPharma operates as an independent, wholly-owned subsidiary of SWK Holdings Corporation (SWKH.OB). Since its founding in 2013, Enteris has advanced into the clinic multiple internal and external programs leveraging its Peptelligence® platform. The technology has been developed and proven effective over the last decade to enable the oral delivery of peptide-based therapeutics as well as other molecules with low oral bioavailability. Enteris BioPharma’s internal clinical product pipeline consists of Ovarest® (oral leuprolide tablet), currently being evaluated in for endometriosis, and Tobrate™ (oral tobramycin tablet) for the treatment of uncomplicated urinary tract infection (uUTI). External market analyses demonstrate projected annual U.S. revenue potential for these two products approximate $1 billion in aggregate. Additionally, Enteris BioPharma’s oral peptide delivery technology is the subject of several active externally sponsored pre-clinical and clinical development programs, the most advanced of which include R-Pharm’s TBRIA, an oral calcitonin for patients with postmenopausal osteoporosis, and an oral formulation of Cara Therapeutics’ KORSUVA™, a potent peripheral kappa opioid receptor agonist with a primary focus for the treatment of pruritus.
keywords:N/AN/A
Total Funding
16
Number of Employees
$1.2M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Enteris BioPharma News
... Register Explosive Growth and Detailed Analysis by Top Manufactures: Amgen Inc., Clonz Biotech, Eli Lilly and Company, Enteris BioPharma.
BOONTON, N.J., April 12, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on...
Enteris BioPharma Highlighted as Game Changer in Drug Development & Delivery Special Feature on Innovative Technologies for Improving Drug...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.1M | 19 | 19% | N/A |
#2 | $3.8M | 19 | -10% | N/A |
#3 | $4.3M | 25 | 0% | N/A |
#4 | $1.7M | 30 | -36% | N/A |
#5 | $6.3M | 31 | -31% | N/A |